ABCL:NSD-AbCellera Biologics Inc (USD)

COMMON STOCK | Others | NSD

Last Closing Price

USD 50.50

Change

-0.40 (-0.79)%

Market Cap

N/A

Volume

0.69M

Average Target Price

USD 51.40 (+1.78%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Currency: USD

Country : United States

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ACWI iShares MSCI ACWI ETF

-0.44 (-0.47%)

 USD14.25B 17.30 N/A
HERO Global X Video Games & Esp..

+0.48 (+1.43%)

 USD0.58B N/A N/A
NFIN Netfin Acquisition Corp

N/A

 USD0.26B N/A N/A
BUG Global X Cybersecurity ETF

+0.24 (+0.84%)

 USD0.20B N/A N/A
HLAL Wahed FTSE USA Shariah ETF

+0.03 (+0.08%)

 USD0.07B N/A N/A
PDEV Principal International Multi-..

N/A

 USD0.06B N/A N/A
OKDCC Eaton Vance Oaktree Diversifie..

N/A

 USD0.05B N/A N/A
UFO Procure Space ETF

-0.01 (-0.04%)

 USD0.04B 5.84 1.68
BSMM Invesco BulletShares (R) 2022 ..

+0.02 (+0.08%)

 USD0.04B N/A N/A
MOGLC Gabelli Media Mogul NextShares

N/A

 USD0.04B 15.80 N/A

ETFs Containing ABCL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Others)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.50% 86% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.50% 86% B 83% B
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Others)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike